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ABSTRACT Forward genetic screens in Mus musculus have proved powerfully informative by revealing
unsuspected mechanisms governing basic biological processes. This approach uses potent chemical muta-
gens, such as N-ethyl-N-nitrosourea (ENU), to randomly induce mutations in mice, which are then bred and
phenotypically screened to identify lines that disrupt a speciﬁc biological process of interest. Although
identifying a mutation using the rich resources of mouse genetics is straightforward, it is unfortunately
neither fast nor cheap. Here we show that detecting newly induced causal variants in a forward genetic
screen can be accelerated dramatically using a methodology that combines multiplex chromosome-speciﬁc
exome capture, next-generation sequencing, rapid mapping, sequence annotation, and variation ﬁltering.
The key innovation of our method is multiplex capture and sequence that allows the simultaneous survey of
both mutant, parental, and background strains in a single experiment. By comparing variants identiﬁed in
mutant offspring with those found in dbSNP, the unmutagenized background strains, and parental lines,
induced causative mutations can be distinguished immediately from preexisting variation or experimental
artifact. Here we demonstrate this approach to ﬁnd the causative mutations induced in four novel ENU lines
identiﬁed from a recent ENU screen. In all four cases, after applying our method, we found six or fewer
putative mutations (and sometimes only a single one). Determining the causative variant was then easily
achieved through standard segregation approaches. We have developed this process into a community
resource that will speed up individual labs’ ability to identify the genetic lesion in mutant mouse lines; all of
our reagents and software tools are open source and available to the broader scientiﬁc community.
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Forward genetic screens in the mouse have uncovered many new
features of mammalian biology. The logic of these studies is straight-
forward. First, a mutagen is used to randomly induce mutations in
mice. Then each line is phenotypically screened to identify lines that
disrupt a speciﬁc biological process of interest. Finally, a putative
causative mutation within a gene is found and then directly shown
to be responsible for the observed phenotype. The fruit of such studies
is a collection of newly identiﬁed genes whose subsequent character-
ization has given us remarkable insights into mammalian biology
(Caspary and Anderson 2006; Cook et al. 2006; Acevedo-Arozena
et al. 2008; Beutler and Moresco 2008; Stottmann et al. 2011).
Although mapping and identifying a mutation using the rich
resources of mouse genetics is straightforward, detecting mutations is
neither fast nor cheap, thanks to two laborious bottlenecks. The ﬁrst
involves the ﬁne chromosomal mapping required to localize a muta-
tion to a small genomic region, and the second entails the Sanger-
based sequencing of genes within that deﬁned region to ﬁnd putative
mutations. Together, these bottlenecks discourage many from using
forward genetics. Second-generation sequencing platforms hold out
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Volume 2 | January 2012 | 143great promise for overcoming these bottlenecks, however, as they
enable individual investigators to harness enormous raw sequencing
power at a dramatically lower cost per sequenced base than traditional
Sanger sequencing (Shendure et al. 2004; Shendure and Ji 2008). In
the vast majority of mutations found to date, the mutagen induces the
critical basepair change in a coding region or splice site, so sequencing
can focus on these regions (exome sequencing). Several groups have
successfully used deep sequencing of single-mutant individuals to
identify causal mutations. The ﬁrst of these groups sequenced
a BAC they generated from mutant DNA; others have performed
whole-exome sequencing, which enabled them to map the mutation
while simultaneously detecting variants (Zhang et al. 2009; Fairﬁeld
et al. 2011; Hilton et al. 2011).
Despite the promise of second-generation sequencing to overcome
these bottlenecks, it has yet to be broadly adopted by the mouse
forward genetics community. One reason may be that the most
popular mutagen used in mouse forward genetics, ENU, induces point
mutations, so when sequencing is used in these lines, two challenges
arise: (1) distinguishing the ENU-induced variants from strain
polymorphisms and (2) identifying real variants (either ENU-induced
or strain-speciﬁc) from technical sequencing errors. Here we in-
vestigate how to best surmount these challenges.
From our experience performing recessive forward genetic screens,
we have made several observations with a practical impact on our
strategy for overcoming these sequencing challenges. In the course of
our screens (schematic in Figure 1A), we look for phenotypes of in-
terest in the generation 3 (G3) litters (Horner and Caspary 2011). We
deﬁne a line once we observe the phenotype in a quarter of the
embryos across three litters and identify at least one G2 male. The
latter requires us to set up blind crosses as we cannot genotype for
the unknown mutation, meaning only one out of every four crosses
results in our seeing the phenotype. Practically, this means that by the
time we establish a line, we have at least four litters, usually more.
Because each litter averages eight embryos, of which around two
individuals are affected, we can easily determine chromosomal linkage
by genome scanning four affected individuals. This allows us to ge-
notype potential carriers in the mouse room, which means immediate
and dramatic reductions in mouse costs.
As we routinely establish chromosomal linkage of our lines,
second-generation sequencing offers us at least two strategies: (1) to
sequence genome-wide and ignore the data from unlinked chromo-
somes or (2) to sequence in the linked region more thoroughly. We
chose the latter, as we could take advantage of the recent development
and validation of methods of isolating target DNA from complex
eukaryotic genomes that can be easily sequenced on second-
generation platforms [Bashiardes et al. 2005; Albert et al. 2007;
Fredriksson et al. 2007; Hodges et al. 2007; Okou et al. 2007, 2009;
Porreca et al. 2007; Bau et al. 2009; Gnirke et al. 2009; Ng et al. 2009,
2010; Nikolaev et al. 2009; Tewhey et al. 2009a, 2009b; Turner et al.
2009; Bainbridge et al. 2010; Patel et al. 2010; and review in Mama-
nova et al. (2010)]. Furthermore, for the same cost as a single sam-
ple, we pursued a multiplex approach that let us both capture and
then sequence multiple samples simultaneously. Because we know
the inheritance pattern of any phenotype-causing mutation in a ge-
netic screen, we reasoned it should be possible to distinguish strain
and sequencing variation by precisely deﬁning a putative mutation
as a de novo variant that occurred at expected ratios in homozygous
and heterozygous individuals, but in neither background strain.
Thus, we were able to validate a method that exploits advances in
isolating target DNA and next-generation sequencing with an added
comparative approach in a cost-effective manner.
We found this strategy greatly enhanced our ability to ﬁnd the
most likely causal variant. Here we show that the major beneﬁto fo u r
multiplexed approach is to eliminate from consideration variants
resulting from strain polymorphisms and technical errors. We took
four novel ENU lines we had identiﬁed in a recent ENU screen, and
for each line, we analyzed six DNA samples, including one from
a previously identiﬁed ENU-induced line (positive control), an affected
mutant embryo, each of the affected embryo’s parents, and each of the
original background strains used in the screen. In all four lines exam-
ined, this approach dramatically reduced the number of candidate
mutations vs. what we would have found had we used the data from
the affected individuals only. Thus, for each of the four lines, we now
have strong candidate lesions that segregate with the relevant pheno-
type. Notably, we found that the sequence comparison between the
affected individuals and the background strains we used dramatically
reduced the number of putative mutations, arguing that simplex
whole-exome approaches would also beneﬁt from this comparison.
MATERIALS AND METHODS
Mouse screen
We performed a recessive ENU mutagenesis screen as previously
described (Garcia-Garcia et al. 2005; Horner and Caspary 2011).
Brieﬂy, we mutagenized C57BL/6J mice and crossed them to FVB/
NJ. We examined G3 embryos for abnormal development of the
nervous system at embryonic day 10.5 (E10.5). Of 121 lines screened,
we found 11 lines with defects in brain and spinal cord morphology.
T h r o u g hag e n o m es c a nu s i n gs i n g l en u c l e o t i d ep o l y m o r p h i s m( S N P )
or simple sequence length polymorphism (SSLP) markers that differ
between the C57BL/6J and FVB/NJ strains, we mapped four lines to
deﬁned intervals on individual chromosomes.
Mouse samples used in our study
Six samples were used for each of the microarray-based genomic
selection (MGS) experiments. Samples used for each line included two
genetic background strains (C57BL/6J and FVB/NJ), one mouse
homozygous for the mutant allele, and its two parents heterozygous
for this allele. For each chromosome, we included the relevant positive
heterozygous control from one of three known strains: Rab23opb2,
Nckap1khlo,o rIft172wim on chr1, chr2, and chr5, respectively
(Eggenschwiler et al. 2001; Huangfu et al. 2003; Rakeman and Ander-
son 2006).
Design of custom microarrays for microarray-based
genomic selection
We used a software package named MOPeD (Microarray Oligonu-
cleotide Probe Designer, http://moped.genetics.emory.edu/)t od e s i g n
all MGS microarrays for this project (Patel et al. 2010). This web-
based software allows individual investigators to easily design custom
genome capture arrays that have been optimized for maskless array
synthesis by Roche NimbleGen. We used the existing mouse chr1,
chr2, and chr5 MOPeD-designed MGS arrays for genomic selection
and obtained the target sequences for the mouse chromosomes from
the UCSC genome browser RefSeq Genes track (mm9 build). We
targeted all the coding and noncoding exons within the region of
interest. Non-overlapping fragments were padded with 100 bp on
either side to ensure proper capturing of splice sites and fragment
ends. For the chr1 chip, we included the exome between the MIT
markers D1MIT251 and D1MIT132, where AB5 mapped, as well as
all exons of the positive control Rab23. For the chr2 chip, we included
the exome between the MIT markers D1MIT81 and D2MIT152
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(candidate region for X5), as well as all exons of the positive control
gene Nckap1. For the chr5 chip, we included the exome between the
MIT markers D5MIT361 and D5MIT20, where Y1 mapped, as well as
all exons of the positive control gene Ift172.
Performing microarray-based genomic selection
MGS was carried out as described previously (Okou et al. 2007, 2009;
Patel et al. 2010) with limited protocol modiﬁcations (described be-
low). We ﬁrst fragmented 5 mg of genomic DNA (mean size 300 bp,
range 200–600 bp) from each of the six different mice, then repaired
the ends and ligated distinct Illumina multiplex adaptors to each
sample. Thus, each mouse sample had a unique multiplex adaptor
tag that allowed simultaneous hybridization to a single MGS array.
The sequence tag allowed us to deconvolute the sequences and, there-
fore, to relate the sequence to a speciﬁc mouse sample after Illumina
sequencing. To ensure equal representation of multiplex adaptor-
tagged DNA fragments from each of the six mice, we performed
quantitative PCR with a probe complementary to the Illumina adap-
tors to accurately assess the quantity of tagged fragments for each
sample prior to hybridization on the MGS array. We then pooled
166.6 ng from each of the six samples (total 1 mg) and hybridized
this pool to the MGS array using the standard protocol. The remain-
ing steps, which include eluting and sequencing the product, were
done via our previously described standard protocol (Okou et al.
2009; Patel et al. 2010).
Illumina sequencing and data analysis
After MGS, the enriched DNA samples were quantitated using qPCR,
and then were denatured and diluted to a concentration of 8 pM. Each
enriched library (having six samples with different index tags) was
sequenced in a single lane of an Illumina HiSequation (100 bp,
multiplexed, paired end for chr5; 100 bp, multiplexed, single end for
chr1 and chr2). After sequencing, the reads were mapped against the
reference sequences for respective regions using Emory Mapper (D. J.
Cutler and M. E. Zwick, personal communication), and variants sites
were identiﬁed. Those variants were then annotated using SeqAnt
(Shetty et al. 2010). Next we used custom Perl scripts to process the
SeqAnt output ﬁles to ﬁrst identify all unique variants (Seqant.parse.
pl), and then to identify and count single nucleotide variants (SNV)
that were homozygous in the mutant individual and not found in
dbSNP or the background strains (Seqant.count.pl), and ﬁnally to list
the genotypes inferred from sequence data for the parents and mutant
offspring (Seqant.genotype.pl).
Sanger sequencing
We veriﬁed the replacement variants we identiﬁed that were within
the genomic interval linked to the phenotype through Sanger
Figure 1 ENU mutagenesis screen and mapping. (A)
ENU-mutagenized C57BL/6J male mice (generation 0,
G0) were crossed to FVB/NJ female mice to generate
G1 males, which were again crossed to FVB/NJ female
mice. G2 females were backcrossed to their respective
G1 fathers to produce G3 embryos, which were
screened for neural phenotypes. Asterisks (*) indicate
ENU-induced mutations, “i” next to asterisk (*i) shows
the inherited ENU-induced mutation, and black and
white lines depict C57BL/6J and FVB/NJ. (B) The caus-
ative mutation segregates with the C57BL/6J DNA,
whose interval can be deﬁned by linked polymorphic
markers. (C) E10.5 wild-type (WT) and mutant embryos
(AB5, M2, X5, and Y1) identiﬁed in ENU screen.
Volume 2 January 2012 | Finding Causal Variants in the Mouse | 145sequencing. For each variant, we ampliﬁed the region surrounding the
variant from genomic DNA from two mutant embryos (primers in
supporting information, Table S2).
Pedigree genotyping
For the top six candidate replacement variants, we found they either
created or destroyed a restriction enzyme polymorphism that we
could use to genotype directly for the variant. The enzyme used to
detect the polymorphisms and their respective genes were: HaeIII
(Ankrd56), HaeIII (Inpp5e), MluCI( Slc2a6), SfcI( Rqcd1), MobI
(Rbm12), and MobI( Duspd15). We genotyped all embryos from be-
tween 32 and 41 litters in each line for the variant. In the course of the
screen, we found “abnormal” embryos that resembled neither the
mutant nor the wild-type phenotype (Table S2). This was likely due
to both spontaneous abnormal development and the high mutation
load in the screen. Consistent with these ideas was our ﬁnding of no
correlation between any variant and any “abnormal” phenotype in
these embryos, suggesting the abnormal embryos were not the result
of the variants we identiﬁed.
RESULTS
Forward genetic screen and mapping
We performed a recessive ENU mutagenesis screen to identify genes
important in the development of the mouse nervous system. We
induced mutations on a C57BL/6J background and crossed to an
FVB/NJ background, as shown in Figure 1A. By examining G3 em-
bryos, we identiﬁed four mutant lines, AB5, M2, X5, and Y1, which
displayed abnormal neural morphology at E10.5 (Figure 1C). These
phenotypes were inherited in an autosomal recessive fashion with
complete penetrance. AB5 mutant embryos were posteriorly truncated
and showed abnormal brain morphology and cranioedema. M2 mu-
tant embryos exhibited midbrain and hindbrain exencephaly, a dys-
morphic neural tube, and anophthalmia or microphthalmia. X5
mutant embryos showed a general developmental delay along with
an open forebrain and midbrain. Y1 mutant embryos displayed whole
brain exencephaly and an undulated neural tube. We genotyped 4
affected G3 embryos using the Illumina mouse low-density linkage
panel for SNP mapping in order to map the location of each putative
recessive mutation to an individual chromosome (Moran et al. 2006).
We found AB5 was linked to chr1; M2 and X5 were both on chr2; and
Y1 was located on chr5.
Targeted sequencing and mutation discovery
Using MOPeD to tailor existing mouse chromosome exome designs,
we performed targeted enrichment of all exons and adjacent intronic
sequences contained within the mapped boundaries for each of the
four mutant lines (Patel et al. 2010). Our previous analysis of single
mouse samples showed we obtained far more sequence depth than
needed to identify a known mutation in a single lane of Illumina
sequencing. To speed the discovery of unknown ENU-induced muta-
tions, we reasoned that, for the same basic cost, we could simulta-
neously sequence six distinct samples on a single microarray during
the enrichment step (multiplexing). These samples included an af-
fected embryo, its two heterozygous parents, one unmutagenized in-
dividual from each of the two background strains used in the screen,
and as a positive control, a distinct, known ENU-induced line that
mapped to the same chromosome. We performed multiplex MGS
followed by sequencing on an Illumina platform for each of the four
mutant lines (Figure 2). After mapping sequence reads, approximately
90% of targeted regions had a sufﬁciently high coverage (.8X) to
identify variant sites for subsequent analysis. Comparable coverage
was obtained for each of the multiplexed lines sequenced. The com-
plete distribution of sequence coverage is shown in Figure S1.
A causative mutation that explains the phenotype we observed had
to be found as homozygous within the mutant line and be newly
induced by the action of the ENU mutagen. To determine whether
such a variant was found within each of our multiplex lines, we ﬁrst
functionally annotated variants for each line using SeqAnt (Shetty
et al. 2010). We then cataloged all homozygous variant sites by func-
tional class for each of the four mutant lines (Table 1, column 3). We
then ﬁltered these variants in two ways. First, because our mutation
would be ENU induced, we expected it should not be a common
polymorphism contained within dbSNP. Applying this ﬁlter to all
the homozygous variant calls for all four mutant lines eliminated
58% (1179 of 2043) of variant sites from further consideration (Table
1, column 4). Second, as the newly induced mutation should not be
found in either of the laboratory background strains (C57BL/6J or
FVB/NJ) used, we next ruled out variants found in these strains from
further consideration. In total, this allowed us to eliminate an addi-
tional 40% (816 of 2043) of variants from further consideration (Table
1, column 5). The remaining 2% (48 of 2043) of variants should thus
include mutations that explain the mutant phenotypes we observed
(Table 1, column 6). Among the remaining 48 variant sites, only 15
Figure 2 Sequencing and analysis pipeline: identifying ENU-induced
mouse mutations with chromosome-speciﬁc exome sequencing. DNA
samples from an affected embryo (muk/muk), the affected embryo’s
parents (+/muk), unmutagenized individuals from the two background
laboratory strains (B1 and B2), and a positive control known mutation
(+/mk) were multiplexed through our targeted sequencing pipeline to
validate our approach and identify novel mutations.
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harbor the mutant alleles. Hence our two-stage screen eliminated
99.3% (2028 of 2043) of variant sites, allowing us to focus on the
0.7% (15 of 2043) of sites across the four lines that were most likely
to be the causative alleles we sought.
Identiﬁcation of mutant alleles
Mapping of the mutant lines during the course of stock maintenance
reduced the size of the region harboring the mutant alleles, allowing us
to eliminate an additional nine replacement variants from further
consideration (Table 2). Two of the lines (AB5 and Y1) had only
a single candidate mutation, whereas another two (M2 and X5) had
two candidate mutations each. We conﬁrmed all six replacement
variants by Sanger sequencing (data not shown). We genotyped each
variant within each line’s existing pedigree and calculated the proba-
bility that the observed correlation of the phenotype-genotype segre-
gation pattern was due to chance (Table 3). In all six cases, the
variants segregated with the respective phenotypes.
In the AB5 mutant line, we found a single T-to-A transversion in
exon 4 of Rqcd1. This change is predicted to result in a leucine being
converted to a stop codon. Among 33 litters examined, all 46 embryos
with the mutant AB5 phenotype were shown to possess the A/A
genotype, suggesting it is causal (Table 3). Providing further evidence
f o rt h i sc o n c l u s i o ni st h eo b s e r v a t i o nt h a tt h eRqcd1 transcript is
found in an expressed sequence tag (EST) library generated from
E8.0 whole-mouse embryo, such that the gene is expressed just prior
to when we observed morphological embryonic anomalies.
For line M2, we found two potential causal variants in genes that
lay 0.63 Mb apart within the candidate interval: a T-to-C transition in
Inpp5e and a C-to-A transversion in Slc2a6. Both mutations are non-
conservative: the transition in Inpp5e changed an aspartic acid to
a glycine, and the transversion in Slc2a6 altered a methionine to an
isoleucine. Among 41 M2 litters examined, we found that all M2
mutants genotyped were homozygous for the C/C Inpp5e and the
A/A Slc2a6 variants, whereas wild-type embryos that appeared wild-
type were never homozygous for the newly induced alleles (Table 3).
Furthermore, there are EST clones representing both genes in mouse
embryonic brain libraries. Taken together, both variants remain can-
didate causal mutations for the observed mutant phenotype. Notably,
Inpp5e-null mice have been characterized and share several aspects of
the M2 phenotype, the most obvious being the exencephaly we see in
both the M2 and Inpp5e-null mice (Jacoby et al. 2009). This correla-
tion suggests that the M2 phenotype may be caused in large part by
the Inpp5e mutation we uncovered. The contribution, if any, of the
Slc2a6 variant to the M2 mutant phenotype awaits more careful phe-
notypic characterization of the M2 line, as well as either another
Slc2a6 allele or a recombination event that eliminates Slc2a6 from
the candidate interval.
We also found two potential variants at two loci for the X5 line.
Within the X5 candidate interval, we found a G-to-A transition in
Rbm12 and a T-to-A transversion in Dusp15. These are predicted to
change amino acid 556 of Rbm12 from threonine to isoleucine and
amino acid 157 of Dusp15 from isoleucine to phenylalanine. We
identiﬁed EST clones of Rbm12 from E8.0 embryonic libraries, but
n Table 1 Results of ﬁltering homozygous variants sites for each mutant line sequenced
Mutant Line Functional Classes
Total Homozygous
Variants In dbSNP
In Background Strains,
Not in dbSNP
Remaining Putative
Mutations
AB5 Replacement 96 80 13 3
AB5 Silent 157 143 12 2
AB5 UTR 331 191 135 5
AB5 Intronic 106 87 17 2
AB5 Intergenic 54 50 4 0
M2 Replacement 43 8 31 4
M2 Silent 19 11 7 1
M2 UTR 73 16 55 2
M2 Intronic 46 18 20 8
M2 Intergenic 40 4 36 0
X5 Replacement 128 59 63 6
X5 Silent 192 128 63 1
X5 UTR 387 231 152 4
X5 Intronic 205 116 86 3
X5 Intergenic 89 34 55 0
Y1 Replacement 17 1 14 2
Y1 Silent 5 0 4 1
Y1 UTR 14 2 11 1
Y1 Intronic 34 0 31 3
Y1 Intergenic 7 0 7 0
n Table 2 Candidate replacement variants in four mutant lines
Mutant Line
Remaining Replacement
Variants
Replacement Variant(s) Within
Mapped Region Candidate Mutation(s)
AB5 3 1 Rqcd1(L159)
M2 4 2 Inpp5e (D511G)
Slc2a6(M99I)
X5 6 2 Rbm12(T556I)
Dusp15(I157F)
Y1 2 1 Ankrd56(S299P)
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databases. Upon genotyping 32 litters from the X5 pedigree, we saw
that mutant animals were always homozygous A/A at Rbm12 (Table
3). In contrast, we found four X5 mutant embryos that were hetero-
zygous (T/A) for the Dusp15 variant. Additionally, we detected two
apparently wild-type embryos that were homozygous (A/A) for the
Dusp15 variant. Thus our genotype data provide greater support for
the variant at Rbm12 vs. the variant at the Dusp15 (Table 3). Although
our ﬁndings might be explained by incomplete penetrance of alleles at
Dusp15, the most parsimonious explanation is that a recombination
event took place, excluding Dusp15 from the candidate interval. Taken
together, we conclude that the variant in Rbm12 is most likely to cause
the X5 phenotype.
For line Y1, we identiﬁed an A-to-G transition in the single exon
gene Ankrd56, which is predicted to change serine 299 of the protein
to proline. We analyzed 33 litters from the Y1 pedigree and found all
of the phenotypic Y1 mutant embryos genotyped G/G, whereas the
nonphenotypic embryos were A/A or G/A (Table 3). We also found
EST clones of Ankrd56 in E8.0 libraries. In total, the strong genotype-
phenotype correlation, the fact that the newly induced variant results
in a nonconservative amino acid change, and the pattern of expression
of the Ankrd56 locus all argue that this variant is likely to underlie the
Y1 phenotype.
In all four lines, we found that the putative causative mutations
were homozygous in the affected mutant embryos and called
heterozygous in their parents in the initial sequencing experiment,
as expected from the recessive inheritance of the mutation. The only
exception was Dusp15, where one parent had very poor depth of
coverage and was not called a heterozygote at the relevant site.
DISCUSSION
Currently, the unparalleled insight into fundamental biological pro-
cesses afforded by phenotype-based screens in the mouse is under-
mined somewhat by the challenges in identifying the affected gene.
Here we accelerate the discovery of likely causative mutations in four
novel ENU-induced lines using a methodology that combines
multiplex chromosome-speciﬁc exome capture, next-generation se-
quencing, rapid mapping, sequence annotation, and variation ﬁltering.
Although additional formal genetic experiments are required to
deﬁnitively demonstrate that we have identiﬁed the causative variant,
the ﬁndings presented here are strong evidence that the replacement
variants we found are the best candidates. Given that each line has
only one or two candidate genes in need of follow up, integrating our
approach more broadly into forward genetic screens in the mouse has
the potential to speed up the gathering of functional information
about the mammalian genome.
Whole-exome and whole-genome sequencing with next-generation
platforms have been used to successfully identify mutations in the
mouse (Zhang et al. 2009; Arnold et al. 2011; Fairﬁeld et al. 2011;
Hilton et al. 2011). Here we show that by using targeted sequencing
of multiple samples, we can reduce the number of candidate caus-
ative mutations to one or two per line. We believe our approach
offers a number of advantages compared with simplex exome se-
quencing of mutant individuals. First, mapping a newly induced
mutation to speciﬁc chromosomes is inexpensive and routinely con-
ducted, regardless of the type of follow-on sequencing performed.
Given the ease and low cost of linkage mapping a newly arising
mutation to a chromosome, as well as the reduction in mouse costs,
the seemingly most natural and efﬁcient strategy for ﬁnding newly
induced mutations would focus sequencing effort solely on those
chromosomes that linkage indicates must harbor a newly induced
mutation. Second, multiplexing six samples on a single MGS micro-
array reduces the cost of capture reagents, while providing valuable
data vital to pinpointing the causative mutations. Furthermore, fo-
cusing on single chromosomes reduces sequencing costs and the
bioinformatics burden associated with whole-exome/whole-genome
datasets. Strikingly, we found that by including the background
strains in the selection and sequencing, we eliminated all but a handful
n Table 3 Segregation data for candidate mutations
Mutant Line Candidate Mutation Phenotype Observed Genotype Number of Mice Probability
AB5 Rqcd1(L159) Wild-type T/A or T/T 201 4.7 · 10258
Wild-type A/A 0
Mutant T/A or T/T 0
Mutant A/A 57
M2 Inpp5e(D511G) Wild-type C/T or T/T 254 1.3 · 10274
Wild-type C/C 0
Mutant C/T or T/T 0
Mutant C/C 80
M2 Slc2a6(M99I) Wild-type C/A or C/C 254 1.3 · 10274
Wild-type A/A 0
Mutant C/A or C/C 0
Mutant A/A 80
X5 Rbm12(T556I) Wild-type A/G or G/G 161 6.7 · 10249
Wild-type A/A 0
Mutant A/G or G/G 0
Mutant A/A 55
X5 Dusp15(I157F) Wild-type T/T or T/A 159 3.4 · 10242
Wild-type A/A 2
Mutant T/T or T/A 4
Mutant A/A 51
Y1 Ankrd56(S299P) Wild-type A/G or A/A 196 1.1 · 10253
Wild-type G/G 0
Mutant A/G or A/A 0
Mutant G/G 42
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putative mutation dramatically faster. The composition of those elim-
inated variants presumably includes both true variant sites that are
unique to a given laboratory mouse strain and false-positive variant
sites that arise due to systematic mismapping and/or imperfections in
genotype calling of next-generation sequencing data. In the case of
a simplex whole-exome/whole-genome sequencing design, where only
the affected individual is sequenced, these additional variants would
have to be pursued with another technology, like Sanger sequencing,
thereby slowing identiﬁcation of the putative mutation. In theory, the
same approach of using the identical sequencing platform for the
background strains could be used for simplex whole-exome analysis.
However, even as sequencing costs continue to decline, the costs of
capture reagents for each additional line are ﬁxed.
Published approaches to identifying causative mutations routinely
rely on screening out variants found in dbSNP (Fairﬁeld et al. 2011;
Hilton et al. 2011). We found that doing so eliminated 58% of the
observed variants. Strikingly, an additional 40% of our detected var-
iants appear to be real polymorphisms present in our laboratory’s
parental strain or technical artifacts not currently seen in dbSNP. In
contrast, our inclusion of the heterozygous parental lines only allowed
us to screen out a handful of sequencing errors that appeared homo-
zygous in the affected mutant embryo but were unobserved in the
parents. Our demonstration of the power gained by sequencing the
background strain using the same sequencing platform as the affected
mouse is important, as it presumably needs to be done only once at
a particular laboratory site. Thus, individual investigators could in
effect have a personalized database of sequence variants for their
background strains in addition to those found in public databases like
dbSNP. Given such a resource, our design could be further modiﬁed
to multiplex affected individuals from distinct lines, which would
further reduce the cost per mutant line.
At a molecular level, the clear advantage of using sequencing is
evident in the M2 line, where two replacement mutations remain
candidates. Using traditional methods, one can easily imagine
narrowing the genomic interval to the same degree and seeing that
the characterized null phenotype of Inpp5e mimics that of M2. Should
M2 fail to complement the Inpp5e-null allele, we would never realize
that Slc2a6 also carries a potentially functional variant. Similarly,
should neither the Inpp5e nor the Slc2a6 variants underlie the M2
phenotype in formal genetic tests, we already know the two UTR
variants that would be the next best candidates (Table 3). Thus, com-
prehensive targeted sequencing enables the identiﬁcation of all possi-
ble mutations that will give us a more thorough understanding of
alleles in the future.
Finally, although we chose to use custom-designed microarrays as
our selection platform because of their easy availability and lower cost,
they do require some standard hardware to process the microarrays.
Chromosome-speciﬁc liquid capture may be another viable strategy
that could be pursued in the future. Our custom microarray designs,
which were not empirically optimized, are freely available for use by
the broader community of mouse geneticists. Using our data from this
experiment will allow immediate improvement in the design of such
arrays to further improve the performance of the targeted enrichment
for future sequencing studies.
The cost savings of our method are clear, albeit difﬁcult to
calculate precisely. The biggest ﬁxed expense in performing forward
genetics is the “cage costs” associated with breeding. Therefore, the
initial chromosomal linkage of newly induced mutations is cost effec-
tive, because it reduces the number of crosses one needs to set up by
75%. While sequencing costs continue to drop precipitously, our
method provides a means to verify results across multiple individuals,
while generating sufﬁcient sequencing coverage for each individual
sample. The result is that we identify only a few real candidate var-
iants, which inherently reduces the costs associated with following
up potential variants. Taken together, our data show that we can
now more efﬁciently pinpoint the most likely causal variants in ENU-
induced lines.
Implications for mouse forward genetics
One valid criticism of forward genetic screens is that, in addition to
identifying novel genes, one can easily invest a great deal of time
discovering a new allele, or even rediscovering a previously identiﬁed
allele, of an already characterized gene. For example, the mutation we
identiﬁed in the M2 line likely represents a new Inpp5e allele. Histor-
ically, the existence of allelic series of speciﬁc loci has proved invalu-
able. This is especially true for structure-function studies, as well as for
understanding the effects of mutations found in humans. Distributing
new alleles of previously characterized genes through the regional
mouse mutant resource centers could be of great value to the mouse
community at large. Still, as one of the main goals of a forward genetic
screen is to identify novel loci that govern basic biological processes,
there are clear advantages to the investigator being able to choose
which lines to work on knowing whether the gene has previously been
characterized. Our method has the potential to change the way the
forward genetics community conducts screens, as we would be able to
ﬁrst systematically ﬁnd the molecular lesions in all lines and then
integrate that information in choosing which lines to pursue. Our
data argue that such an ideal is within reach.
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